Public Employees Retirement Association of Colorado Grows Stock Position in Cambrex Co. (NYSE:CBM)

Public Employees Retirement Association of Colorado lifted its stake in Cambrex Co. (NYSE:CBM) by 12.3% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 445,305 shares of the biotechnology company’s stock after buying an additional 48,935 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Cambrex were worth $20,845,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of CBM. Marshall Wace LLP bought a new stake in shares of Cambrex in the first quarter worth about $30,000. Flagship Harbor Advisors LLC grew its stake in shares of Cambrex by 2,725.8% in the first quarter. Flagship Harbor Advisors LLC now owns 876 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 845 shares during the last quarter. Private Capital Group LLC grew its stake in shares of Cambrex by 31.6% in the first quarter. Private Capital Group LLC now owns 1,978 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 475 shares during the last quarter. Hilton Capital Management LLC bought a new stake in shares of Cambrex in the first quarter worth about $94,000. Finally, Palouse Capital Management Inc. bought a new stake in shares of Cambrex in the first quarter worth about $242,000.

Cambrex stock traded up $0.11 during trading hours on Wednesday, hitting $60.21. 36,918 shares of the stock traded hands, compared to its average volume of 405,688. The business’s 50-day moving average price is $46.96. The company has a current ratio of 2.44, a quick ratio of 1.77 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $2.02 billion, a P/E ratio of 21.73, a PEG ratio of 4.69 and a beta of 2.36. Cambrex Co. has a one year low of $33.80 and a one year high of $69.43.

Several research firms recently issued reports on CBM. William Blair cut Cambrex from an “outperform” rating to a “market perform” rating and set a $60.00 target price on the stock. in a research note on Wednesday, August 7th. Zacks Investment Research cut Cambrex from a “buy” rating to a “hold” rating in a research note on Wednesday, July 24th. First Analysis cut Cambrex from a “strong-buy” rating to an “outperform” rating and raised their target price for the stock from $45.00 to $55.00 in a research note on Tuesday, May 7th. Robert W. Baird cut Cambrex from an “outperform” rating to a “neutral” rating and set a $44.00 target price on the stock. in a research note on Friday, May 3rd. They noted that the move was a valuation call. Finally, ValuEngine raised Cambrex from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 8th. Five equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $52.00.

About Cambrex

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.

Recommended Story: Risk Tolerance

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.